Cancer Biospecimen Acquisition and Biorepository

癌症生物样本采集和生物样本库

• 批准号: 9122698
• 负责人: Israel DAVID GOLDMAN
• 金额: $ 10.56万
• 依托单位: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-09-01 至 2018-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9122698
• 关键词: Albert Einstein Cancer Center; Basic Science; Benign; Blood; Breast; Cancer Center; Cell Nucleus; Cervical; Characteristics; Clinical; Clinical Research; Collaborations; Colon; Computerized Medical Record; Consent; Ensure; Epidemiology; Evaluation; Funding; Goals; Head and Neck Cancer; Health; Hematologic Neoplasms; Housing; Human; Individual; Informatics; Informed Consent; Institutes; Institution; Instruction; Joints; Knowledge; Laboratories; Link; Liquid substance; Lung; Malignant - descriptor; Malignant Neoplasms; Medical; Medical Research; Medical center; Mission; Monitor; Morbidity - disease rate; NCI-Designated Cancer Center; Normal tissue morphology; Online Systems; Ovarian Neuroendocrine Neoplasm; Parents; Patients; Population Research; Positioning Attribute; Procedures; Process; Protocols documentation; Quality Control; Records; Reporting; Research Personnel; Resource Sharing; Resources; Sampling; Secure; Security; Services; Solid Neoplasm; Specimen; Surgical Pathology; Technology; Tissue Donations; Tissues; Translational Research; Tumor Bank; United States National Institutes of Health; anticancer research; biobank; follow-up; meetings; member; mortality; prospective; sample collection; satisfaction

The goal of the AECC Cancer Biospecimen Acquisition and Biorepository Resource (CBABR) is to provide a centralized unit that meets the best practices of the NCI for high quality biospecimens for cancer research. The CBABR oversees the procurement of malignant, benign, diseased and uninvolved (normal) tissues from both solid and hematological tumors for use by AECC and other investigators. The CBABR has been organized through the consolidation of multiple federated cancer associated Institutional biobanks into a cohesive cancer oriented tissue acquisition and storage biobank that is the nucleus for prospective sample collection. The CBABR is a joint effort of AECC, the Einstein CTSA and other NIH funded centers at Einstein and is supported by several Institutional initiatives including a universal opt-in consent process in use by Einstein's clinical partner, Montefiore Medical Center, dedicated staffing for tissue acquisition in cooperation with Montefiore Surgical Pathology, Clinical Research Informatics support linking samples to medical and research records, and dedicated secure storage space utilizing the most advanced energy efficient freezer technology. A web-based application has been developed that allows investigators to determine if tissue exists in the CBABR with necessary phenotypic characteristics for their studies. The CBABR focus has been on head and neck cancer, breast, colon, lung, cervical and ovarian, neuroendocrine tumors, and hematological tumors. It currently houses 67,704 samples, including 5,704 samples collected since the institution of the new CBABR in late 2011, all of which are available for use by investigators. The CBABR process encompasses patient informed consent at initial cancer evaluation, planned universal "opt-in" consent procedures, patient medical and health information that is annotated to the biospecimens, centralized management of specimen collection, processing and storage, and multiple levels of security and protection of the resource through the parent CTSA biorepository including 24/7 monitoring and alarmed redundant backups. A CBABR Scientific Review Board (SRB) has been constituted to evaluate scientific and technical merit of applications for use of biospecimens that reports to the AECC Protocol Review and Monitoring Committee (PRMC) to approve and, when necessary, prioritize proposed tissue usage. Mechanisms for requested collaborations from outside investigators have been established as well. An institutional initiative will track the informed consent process and perform follow up queries on contributors to the CBSR to assess patient knowledge and satisfaction.

AECC 癌症生物样本采集和生物样本库资源 (CBABR) 的目标是提供一个符合 NCI 最佳实践的集中单位，为癌症研究提供高质量生物样本。 CBABR 负责监督实体肿瘤和血液肿瘤中恶性、良性、患病和未受累（正常）组织的采购，供 AECC 和其他研究人员使用。 CBABR 是通过将多个联合癌症相关机构生物库整合为一个有凝聚力的癌症导向组织采集和存储生物库而组织起来的，该生物库是前瞻性样本收集的核心。 CBABR 是 AECC、爱因斯坦 CTSA 和其他 NIH 资助的爱因斯坦中心的共同努力，并得到多项机构举措的支持，包括爱因斯坦临床合作伙伴 Montefiore 医疗中心使用的普遍选择同意流程、组织采集的专门人员配置临床研究信息学与 Montefiore Surgical Pathology 合作，支持将样本与医疗和研究记录关联起来，并利用最先进的节能冷冻技术提供专用的安全存储空间。一个基于网络的应用程序已经开发出来，允许研究人员确定 CBABR 中是否存在具有研究所需表型特征的组织。 CBABR 的重点是头颈癌、乳腺癌、结肠癌、肺癌、宫颈癌和卵巢癌、神经内分泌肿瘤和血液肿瘤。目前，该中心保存有 67,704 个样本，其中包括自 2011 年底新 CBABR 建立以来收集的 5,704 个样本，所有这些样本都可供调查人员使用。 CBABR 流程包括初始癌症评估时的患者知情同意、计划的普遍“选择加入” 同意程序、生物样本上注释的患者医疗和健康信息， 标本采集、处理、保存集中管理，多级安全保障 通过母 CTSA 生物样本库保护资源，包括 24/7 监控和警报 冗余备份。 CBABR 科学审查委员会 (SRB) 已成立，以评估科学和 向 AECC 协议审查报告的生物样本使用申请的技术优点 监督委员会 (PRMC) 批准并在必要时优先考虑拟议的组织使用。 还建立了请求外部调查人员合作的机制。一个 机构倡议将跟踪知情同意过程并对贡献者进行后续询问 CBSR 评估患者的知识和满意度。